CoChat

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

Open access

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Objective: The objective of this study is to evaluate efficacy and safety of SPN-812 (extended-release viloxazine) for ADHD in children aged 6 to 12 years. Method: In an 8-week study, 222 participants were randomized to placebo or SPN-812 100, 200, 300, or 400 mg/day. Measurements included ADHD Rating Scale (RS)-IV total score and Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) scores. Safety assessments included laboratory and electrocardiogram (ECG) measurements, suicidality monitoring (Columbia-Suicide Severity Rating Scale), and adverse event (AE) reporting. Results: Significant improvements in ADHD-RS-IV total score were observed for 200, 300, and 400 mg dose groups versus placebo ( p < .05; effect size [ES] = 0.547, 0.596, and 0.623). CGI-I score for the 300 mg group and CGI-S score for all SPN-812 groups except for 100 mg improved significantly ( p < .05) versus placebo. The most frequent AEs (≥15%) were somnolence, headache, and decreased appetite. Conclusion: SPN-812 significantly reduced the severity of ADHD symptoms and was well tolerated. The efficacy and safety of SPN-812 are being investigated in Phase III trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1087054719836159

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Schematic overview of the study design. Note. V = visit; QD = once daily. aParticipants receiving ADHD drug therapy at Screening were given at least 7 days to wash out. bMaintenance period began at Weeks 2, 3, 4, or 5, depending on the dose group.
Figure 1. Schematic overview of the study design. Note. V = visit; QD = once daily. aParticipants receiving ADHD drug therapy at Screening were given at least 7 days to wash out. bMaintenance period began at Weeks 2, 3, 4, or 5, depending on the dose group.CC BY-NC · PubMed Central
Figure 2. Subject disposition. Note. ITT = intention-to-treat; PP = per-protocol. aOne participant randomized to SPN-812 300 mg/day received 100 mg/day throughout the study; this participant is included in the 100 mg/day group in all safety analyses, but in the 300 mg/day group in all analyses based on the ITT population.
Figure 2. Subject disposition. Note. ITT = intention-to-treat; PP = per-protocol. aOne participant randomized to SPN-812 300 mg/day received 100 mg/day throughout the study; this participant is included in the 100 mg/day group in all safety analyses, but in the 300 mg/day group in all analyses based on the ITT population.CC BY-NC · PubMed Central
Figure 3. Mean change from Baseline over time in ADHD-RS-IV total score by treatment group (ITT population). Note. ADHD-RS-IV = ADHD Rating Scale-IV; ITT = intention-to-treat; CFB = change from Baseline; ANOVA = analysis of variance. Statistics based on sensitivity analysis using a mixed model for repeated measures analysis: *p < .05 for the 100, 200, 300, and 400 mg/day dose groups versus placebo (ANOVA). †p < .05 only for the 200, 300, and 400 mg/day dose groups versus placebo (ANOVA). ‡p < .05 only for the 300 and 400 mg/day dose groups versus placebo (ANOVA).
Figure 3. Mean change from Baseline over time in ADHD-RS-IV total score by treatment group (ITT population). Note. ADHD-RS-IV = ADHD Rating Scale-IV; ITT = intention-to-treat; CFB = change from Baseline; ANOVA = analysis of variance. Statistics based on sensitivity analysis using a mixed model for repeated measures analysis: *p < .05 for the 100, 200, 300, and 400 mg/day dose groups versus placebo (ANOVA). †p < .05 only for the 200, 300, and 400 mg/day dose groups versus placebo (ANOVA). ‡p < .05 only for the 300 and 400 mg/day dose groups versus placebo (ANOVA).CC BY-NC · PubMed Central
Figure 4. Mean CGI-I scores by treatment group (ITT population). Note. CGI-I = Clinical Global Impressions Scale-Improvement; ITT = intention-to-treat; EOS = end of study. Statistics based on analysis at EOS: *p < .05 for the 300 mg/day dose group versus placebo (ANOVA, unadjusted p value).
Figure 4. Mean CGI-I scores by treatment group (ITT population). Note. CGI-I = Clinical Global Impressions Scale-Improvement; ITT = intention-to-treat; EOS = end of study. Statistics based on analysis at EOS: *p < .05 for the 300 mg/day dose group versus placebo (ANOVA, unadjusted p value).CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 3

  1. Johnson J. K. Saylor K. Brittain S. T. Tulloch G. Liranso T. (2015, 10 26-31). Double-blind, randomized, placebo-controlled study of immediate-release viloxazine (SPN-812 IR) as a novel non-stimulant therapy in adults with attention-deficit/hyperactivity disorder (ADHD). Poster presented at American Academy of Child and Adolescent Psychiatry, San Antonio, TX.
  2. Johnson J. K. Saylor K. Brittain S. T. Tulloch G. Liranso T. (2017, 10 23-28). A double-blind, placebo-controlled, dose-ranging study of extended-release viloxazine (SPN-812 ER) in children with ADHD. Abstract presented at American Academy of Child and Adolescent Psychiatry, Washington, DC.
  3. Shire US Inc. (2017). INTUNIV® (guanfacine) extended-release tablets, for oral use, prescribing information. Lexington, MA: Author.

Cited by

See all 66

Metadata

Authors
Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H.
Affiliations
  • Supernus Pharmaceuticals (United States) (US)
  • NeuroScience, Inc., Herndon, VA, USA
  • Kennedy Krieger Institute (US)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Nasser, Azmi
Venue
Journal of Attention Disorders
Published
2019-03-29
Volume
24
Issue
2
Pages
348-358
ISSN
  • 1087-0547 (ISSN-L)
  • 1557-1246
OpenAlex
W2933452394
Cited by
62
References
24
Citations by year
2026: 3 · 2025: 6 · 2024: 10 · 2023: 7 · 2022: 13 · 2021: 15 · 2020: 7 · 2019: 1
FWCI
7.15
Type
journal article
Language
en
Open access
Locations
  • Journal of Attention Disorders (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Supernus Pharmaceuticals, Inc.
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
attention deficit hyperactivity disorder, children, ADHD-RS-IV, Clinical Global Impression Scale, suicidality, adverse events, sleepiness, drug efficacy, drug safety, norepinephrine reuptake inhibitors
MeSH terms
Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Delayed-Action Preparations, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Viloxazine, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD. https://app.cochat.ai/papers/10.1177/1087054719836159
The paper
Johnson, J. K., Liranso, T., Saylor, K., Tulloch, G., Adewole, T., Schwabe, S., Nasser, A., Findling, R. L., & Newcorn, J. H. (2020). A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD. Journal of Attention Disorders. https://doi.org/10.1177/1087054719836159

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.